Preclinical models of HPV+ and HPV- HNSCC in mice: An immune clearance of HPV+ HNSCC

Head and Neck

Volumn 31, Issue 7, 2009, Pages 911-918

  Williams, Robin ^a   Lee, Dong Wook ^a   Elzey, Bennett D ^b,c   Anderson, Mary E ^a   Hostager, Bruce S ^d   Lee, John H ^a  

^a UNIVERSITY OF IOWA   (United States)

^b PURDUE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Antitumor immune response; Head; HPV; Mouse model; Squamous cell cancer

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; HEAD AND NECK CARCINOMA; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL; WART VIRUS;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, VIRAL; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; MICE; MICE, INBRED C57BL; TUMOR BURDEN;

EID: 67650505637     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21040     Document Type: Article

References (15)

1. Johnson N. Tobacco use and oral cancer: a global perspective. J Dent Educ 2001;65:328-339.
2. Buckley JG, Ferlito A, Shaha AR, Rinaldo A. The treatment of distant metastases in head and neck cancer - present and future. ORL J Otorhinolaryngol Relat Spec 2001;63:259-264. (Pubitemid 32620181)
3. Smith EM, Ritchie JM, Summersgill KF, et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004;108:766-772. (Pubitemid 38076410)
4. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-475. (Pubitemid 40270113)
5. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003;104:336-344. (Pubitemid 36249816)
6. Ioka A, Tsukuma H, Ajiki W, Oshima A. Trends in head and neck cancer incidence in Japan during 1965-1999. Jpn J Clin Oncol 2005;35:45-47.
7. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-619. (Pubitemid 351264356)
8. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-269.
9. Spanos WC, Hoover A, Harris GF, et al. The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage- independent growth and synergizes with ras for invasive growth. J Virol 2008;82:2493-2500. (Pubitemid 351293550)
10. Hoover AC, Spanos WC, Harris GF, et al. The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Arch Otolaryngol Head Neck Surg 2007;133:495-502. (Pubitemid 46799788)
11. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992;68:869-877.
12. Welters M. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003;63:636-641. (Pubitemid 36158141)
13. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus- associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500-1510. (Pubitemid 30757423)
14. Cobo F, Garcia C, Talavera P, et al. Human papillomavirus associated with papillary squamous cell carcinoma of the oropharynx in a renal transplant recipient. Infection 2006;34:176-180. (Pubitemid 43979669)
15. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-26. (Pubitemid 26010379)